Shots:

• The launch of Tacrolimus capsules follows the approval of the US FDA in Nov’20 and emphasizes Biocon activity to make affordable healthcare accessible
• Tacrolimus is particularly effective in treating patients of renal transplant
• Tacrolimus- a calcineurin inhibitor immunosuppressant used to treat organ transplant patients- reduces the body’s ability to reject a transplanted organ

Click here ­to­ read full press release/ article | Ref: Biocon | Image: Business Standard